# A Study To Investigate The Safety And Toleration Of Multiple Oral Doses Of PF-03654764 In Combination With Fexofenadine In Healthy Subjects

> **NCT01298505** · PHASE1 · TERMINATED · sponsor: **Pfizer** · enrollment: 36 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** PF-03654764 2.5mg plus fexofenadine 60mg
- **DRUG:** PF-03654764 5mg plus fexofenadine 60mg
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01298505
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-06-04
- **Primary completion:** 2010-06-04
- **Final completion:** 2010-06-04
- **Target enrollment:** 36 (ACTUAL)
- **Why stopped:** This study was stopped due to lack of evidence for clinical efficacy.
- **Last updated:** 2019-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01298505

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01298505, "A Study To Investigate The Safety And Toleration Of Multiple Oral Doses Of PF-03654764 In Combination With Fexofenadine In Healthy Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01298505. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*